StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

Equities research analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Aptose Biosciences in a research report on Friday, June 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Aptose Biosciences Stock Performance

Shares of APTO opened at $0.41 on Thursday. The firm has a market capitalization of $8.17 million, a price-to-earnings ratio of -0.07 and a beta of 1.25. The business’s fifty day moving average price is $0.46 and its two-hundred day moving average price is $0.90. Aptose Biosciences has a 52 week low of $0.33 and a 52 week high of $3.32.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.15. As a group, research analysts forecast that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.